Dilated Cardiomyopathy

Detailed Overview

DCM leads to progressive decline in ventricular contractile function. The compensatory mechanisms, including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), initially maintain cardiac output but eventually lead to maladaptive remodeling, worsening volume overload, and heart failure. The structural changes predispose the patient to life-threatening ventricular arrhythmias, conduction blocks, and mural thrombus formation.

Epidemiology & Demographics

Prevalence is estimated at 1 in 250 to 1 in 2,500 individuals. It occurs at any age but is most commonly diagnosed in the third to fourth decades of life. It is more prevalent and carries a worse prognosis in men and Black patients.

Etiological Mechanism

Approximately 20-35% of cases are familial, most commonly inherited in an autosomal dominant pattern with mutations in genes like TTN (titin). Secondary causes include viral myocarditis (Coxsackie B, Adenovirus), cardiotoxins (anthracyclines, chronic alcohol abuse, cocaine), metabolic disorders, and peripartum state.

Primary Causes

Genetic Mutations (e.g., TTN, LMNA, MYH7)

Viral Myocarditis

Alcohol/Substance Abuse

Chemotherapy Toxicity (e.g., Doxorubicin)

Idiopathic

• Family History: First-degree relative with unexplained heart failure or sudden cardiac death.
• Heavy Alcohol Consumption: Chronic intake of >80g of alcohol/day for >5 years.
• Anthracycline Exposure: Cumulative doses of Doxorubicin > 400 mg/m² significantly increase risk.
• Pregnancy: Specifically the last month of pregnancy or first 5 months postpartum.

The primary insult (genetic, infectious, or toxic) causes myocyte damage and necrosis. This triggers a reparative process leading to interstitial fibrosis and myocardial remodeling. The loss of functional myocytes results in decreased contractility. To compensate for reduced stroke volume, the ventricle dilates (eccentric hypertrophy). Wall stress increases according to Laplace's law, further increasing oxygen demand and neurohormonal activation, creating a vicious cycle of progressive systolic dysfunction and progressive chamber dilation.

Characteristic Clinical Presentation

• Dyspnea on Exertion: Shortness of breath during physical activity due to reduced cardiac output and pulmonary congestion.
• Orthopnea: Shortness of breath when lying flat, indicating elevated left ventricular filling pressures.
• Fatigue: Profound tiredness due to inadequate systemic perfusion.
• Peripheral Edema: Swelling in the lower extremities due to right-sided heart failure component.

Physical Examination Signs

• Displaced Point of Maximal Impulse (PMI) laterally and inferiorly
• S3 Gallop (protodiastolic sound)
• Jugular Venous Distention (JVD)
• Holosystolic murmur of functional mitral regurgitation

• Congestive Heart Failure: Progressive inability of the heart to meet the body's demands.
• Arrhythmias: Atrial fibrillation and life-threatening ventricular tachycardias.
• Thromboembolism: Formation of mural thrombi due to blood stasis, leading to stroke or peripheral emboli.
• Sudden Cardiac Death: Fatal ventricular arrhythmias often due to extensive myocardial fibrosis.

Diagnostic Criteria & Guidelines

Diagnosis requires echocardiographic evidence of left ventricular enlargement (LVEDD > 117% of predicted value for age and body surface area) and systolic dysfunction (LVEF < 45% or fractional shortening < 25%). Ischemic etiology must be ruled out (usually via coronary angiography).

Differential Diagnosis

• Ischemic Cardiomyopathy
• Hypertensive Heart Disease
• Valvular Heart Disease (e.g., severe Aortic Regurgitation)
• Hypertrophic Cardiomyopathy (end-stage, 'burned-out' phase)

Laboratory Tests & Biomarkers

• B-type Natriuretic Peptide (BNP): Elevated (typically >100 pg/mL) or NT-proBNP >300 pg/mL
• Troponin: May be chronically mildly elevated or normal
• Comprehensive Metabolic Panel: May show elevated creatinine/BUN or transaminases if hypoperfusion exists

Imaging Modalities & Findings

• Transthoracic Echocardiogram (TTE):
• Cardiac MRI (CMR) with Late Gadolinium Enhancement:
• Chest X-Ray:

• NYHA Class I
  No limitation of physical activity. Ordinary activity does not cause symptoms.
• NYHA Class II
  Slight limitation. Comfortable at rest, but ordinary activity causes symptoms.
• NYHA Class III
  Marked limitation. Comfortable at rest, but less than ordinary activity causes symptoms.
• NYHA Class IV
  Unable to carry on physical activity without discomfort. Symptoms present at rest.

Second-Line & Adjunctive Therapy

Ivabradine (5 mg BID) if resting heart rate remains >70 bpm on max beta-blocker. Digoxin (0.125-0.25 mg daily) for symptomatic control in HFrEF with atrial fibrillation. Implantable Cardioverter Defibrillator (ICD) for primary prevention of SCD if LVEF remains <=35% despite 3 months of optimal GDMT.

Surgical & Procedural Management

Cardiac Resynchronization Therapy (CRT) if QRS > 150ms and LBBB morphology. Left Ventricular Assist Device (LVAD) as bridge to transplant or destination therapy for end-stage refactory HF. Orthotopic Heart Transplantation is the definitive surgical treatment.

Recommended Lifestyle Changes

• Sodium restriction (< 2-3 g/day) and fluid restriction (< 2L/day) in advanced failure.
• Complete abstinence from alcohol and illicit drugs, especially if suspected etiology.
• Cardiac rehabilitation and symptom-guided aerobic exercise.

Patient Counseling & Advice

Educate the patient to take daily morning weights and notify the clinician if weight increases by >2-3 lbs in 24 hours or 5 lbs in a week. Stress the critical importance of taking all HF medications exactly as prescribed, even if feeling well, to prevent disease progression.

Follow-Up & Monitoring Schedule

Echocardiogram every 3-6 months during titration of GDMT to assess for reverse remodeling. Renal function (creatinine, potassium) checked 1-2 weeks after initiating or titrating RAAS inhibitors/MRAs. Routine clinical visits every 3-6 months once stable.

Preventive Strategies

Screen first-degree relatives of patients with idiopathic or familial DCM with clinical exam, ECG, and echocardiography. Avoid excessive alcohol consumption and cardiotoxic medications if possible.

Prognosis has dramatically improved with modern GDMT. The 5-year survival rate is now around 70-80%. Patients showing reverse remodeling (improvement in LVEF) on medical therapy have excellent long-term survival. Prognosis is worse if LVEF remains <20%.